Haya Therapeutics Company
Haya Therapeutics focuses on blocking long non-coding RNAs found in the human genome, which play a role in fibrotic diseases and other age-related health conditions, like cancer. Haya aims to identify new targets and drug candidates that could be more effective and have a greater efficacy profile than current treatments. The precision therapeutics company uses RNA-targeting drugs, such as modified antisense oligonucleotides, to inhibit long non-coding RNAs.
Technology:
Gene Therapy
Industry:
BioTech
Headquarters:
Lausanne
Founded Date:
2017
Employees Number:
1-10
Investors Number:
8
Total Funding:
20328986
Last Funding Date:
2021
Last Funding Type:
Seed
Register and Claim Ownership